1949 was a momentous year—astronomer Fred Hoyle coined the term Big Bang, the North Atlantic Treaty Organization (NATO) was formed, and Rodgers and Hammerstein’s classic musical South Pacific opened on Broadway.1 Much less recognized was the publication of an essay by Richard Asher, FRCP, titled the “Seven Sins of Medicine.”2 Although it’s over 75 years…
Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.
Symptom checkers, telehealth and more—here are insights into the effects new technologies are having on rheumatology.
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
Wondering how best to care for an adult patient with juvenile idiopathic arthritis-associated uveitis or a pediatric patient with early-onset osteoarthritis? Unsure how to manage a 23-year-old with chronic nonbacterial osteomyelitis or an 8-year-old with tophaceous gout due to Lesch-Nyhan syndrome? Ask a Med-Peds rheumatologist. What Is a Med-Peds Rheumatologist? Med-Peds rheumatologists in the U.S….
Methotrexate—an affordable, established drug for rheumatoid arthritis—may also be helpful for patients suffering from osteoarthritis (OA) of the hand, a recent study reports.1 Treatment of hand OA and inflammation with 20 mg of methotrexate for six months had a moderate, but potentially clinically meaningful, effect on reducing pain and stiffness in patients with symptomatic hand…
Current knowledge of receptor-ligand interactions, cell signaling, and transcriptional regulation derive from studies of type I interferon. The design of novel therapeutics is informed by the advances in investigation of type I interferon, with the potential for important impacts on patient management.
In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Editor’s note: Rheumatologists who are outstanding researchers, educators and/or clinicians, who provide consistently exceptional care to patients, have achieved a level of distinction in the field and serve as role models for colleagues and trainees are highlighted in this recurring series. Be curious. Listen to your patients. Demonstrate empathy. These traits, according to Herbert S.B….